Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

U.S. researchers present new PKR1/PKR2 receptor antagonists

July 27, 2010

Clinical phase III data presented on linagliptin in type 2 diabetes

July 27, 2010

Cerenis Therapeutics raises funds to develop HDL therapies

July 26, 2010

Almirall and Pfizer join to commercialize Conbriza for osteoporosis in Spain

July 26, 2010

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

July 26, 2010

Sirtris Pharmaceuticals describes new SIRT modulators

July 23, 2010

CP-404 successfully completes pilot phase I study for obesity

July 23, 2010

Tarsa advances phase III oral calcitonin trial in postmenopausal osteoporosis

July 23, 2010

Repros Therapeutics to start low-dose study of Proellex

July 23, 2010

Insulin degludec improves glucemic control in phase II trials in type 1 and 2 diabetes

July 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...